Paul H. Gillard

Waver, VLG, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Enhancing vaccine clinical trials participation among elderly: challenges and strategies.

Enhancing vaccine clinical trials participation among elderly: challenges and strategies.

Journal: Trials

Published: October 28, 2024

Subsequent AS01-adjuvanted vaccinations induce similar transcriptional responses in populations with different disease statuses.

Subsequent AS01-adjuvanted vaccinations induce similar transcriptional responses in populations with different disease statuses.

Journal: PloS one

Published: March 25, 2022

Clinically- versus serologically-identified varicella: A hidden infection burden. A ten-year follow-up from a randomized study in varicella-endemic countries.

Clinically- versus serologically-identified varicella: A hidden infection burden. A ten-year follow-up from a randomized study in varicella-endemic countries.

Journal: Human vaccines & immunotherapeutics

Published: June 28, 2021

Correlation of protection against varicella in a randomized Phase III varicella-containing vaccine efficacy trial in healthy infants.

Correlation of protection against varicella in a randomized Phase III varicella-containing vaccine efficacy trial in healthy infants.

Journal: Vaccine

Published: October 14, 2020

Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis.

Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis.

Journal: The New England journal of medicine

Published: October 30, 2019

Comparison of a glycoprotein E-based ELISA with a varicella-zoster whole-virus ELISA for the quantification of varicella vaccine immune responses in young children.

Comparison of a glycoprotein E-based ELISA with a varicella-zoster whole-virus ELISA for the quantification of varicella vaccine immune responses in young children.

Journal: Vaccine

Published: October 10, 2019

Assessment of Mumps Virus-Specific Antibodies: Comparison of Plaque Reduction Neutralization Test and Enzyme-Linked Immunosorbent Assay Estimates.

Assessment of Mumps Virus-Specific Antibodies: Comparison of Plaque Reduction Neutralization Test and Enzyme-Linked Immunosorbent Assay Estimates.

Journal: The Journal of infectious diseases

Published: March 29, 2019

Immunogenicity and safety of the diphtheria, pertussis, tetanus and inactivated poliovirus vaccine when co-administered with the human rotavirus vaccine (Rotarix) in healthy Japanese infants: a phase IV randomized study.

Immunogenicity and safety of the diphtheria, pertussis, tetanus and inactivated poliovirus vaccine when co-administered with the human rotavirus vaccine (Rotarix) in healthy Japanese infants: a phase IV randomized study.

Journal: Human vaccines & immunotherapeutics

Published: February 21, 2019

Response to: A Phase III open-label, randomized, active controlled clinical study to assess safety, immunogenicity and lot-to-lot consistency of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants.

Response to: A Phase III open-label, randomized, active controlled clinical study to assess safety, immunogenicity and lot-to-lot consistency of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants.

Journal: Vaccine

Published: December 14, 2018

Safety and immunogenicity of a varicella vaccine without human serum albumin (HSA) versus a HSA-containing formulation administered in the second year of life: a phase III, double-blind, randomized study.

Safety and immunogenicity of a varicella vaccine without human serum albumin (HSA) versus a HSA-containing formulation administered in the second year of life: a phase III, double-blind, randomized study.

Journal: BMC pediatrics

Published: October 24, 2018

Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis.

Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis.

Journal: The New England journal of medicine

Published: October 04, 2018

Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study.

Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study.

Journal: Journal of the Pediatric Infectious Diseases Society

Published: August 23, 2018

Showing 1-12 of 25

Last Updated: 09/26/2026